---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-26-000012"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:29:18.920815+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026

## Summary
- Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.
- Compensation includes $500,000 base salary, 55% target bonus, RSUs and PSUs each valued at $1.5 million.
- RSU vests over four years; PSU vests upon achievement of performance objectives set by Compensation Committee.
- No family relationships or material transactions with the company or its other officers disclosed.

## SEC filing metadata
- accession: 0001384101-26-000012
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000012/0001384101-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410126000012/vcyt-20260313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-26-000012
- JSON: https://secwatch.observer/filing/0001384101-26-000012.json
- Plain text: https://secwatch.observer/filing/0001384101-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.